News | September 22, 2023
Natural Biogenex performs inauguration at Tumkur unit
This production block consists of chemical synthesis reactions and clean rooms areas to produce final API
This production block consists of chemical synthesis reactions and clean rooms areas to produce final API
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Nous-209 has been developed using the Nouscom's viral vector platform
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Natural Capsules Limited's shareholding will be reduced to 89.99%
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
The new project further expands the partner's long-term collaboration on new technologies for R&D
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Subscribe To Our Newsletter & Stay Updated
